Whitehawk Therapeutics, Inc. (WHWK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Whitehawk Therapeutics, Inc. stock (WHWK) is currently trading at $3.59. Whitehawk Therapeutics, Inc. PS ratio (Price-to-Sales) is 23.71. Analyst consensus price target for WHWK is $5.67. WallStSmart rates WHWK as Sell.
- WHWK PE ratio analysis and historical PE chart
- WHWK PS ratio (Price-to-Sales) history and trend
- WHWK intrinsic value — DCF, Graham Number, EPV models
- WHWK stock price prediction 2025 2026 2027 2028 2029 2030
- WHWK fair value vs current price
- WHWK insider transactions and insider buying
- Is WHWK undervalued or overvalued?
- Whitehawk Therapeutics, Inc. financial analysis — revenue, earnings, cash flow
- WHWK Piotroski F-Score and Altman Z-Score
- WHWK analyst price target and Smart Rating
Whitehawk Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Whitehawk Therapeutics, Inc. (WHWK) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Whitehawk Therapeutics, Inc. (WHWK) Key Strengths (2)
76.04% of shares held by major funds and institutions
Trading at 1.24x book value, attractively priced
Supporting Valuation Data
Whitehawk Therapeutics, Inc. (WHWK) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -100.00%, a shrinking business
Company is losing money with a negative profit margin
Very expensive at 23.7x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Whitehawk Therapeutics, Inc. (WHWK) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.24) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (23.71) suggest expensive pricing. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -21.80%, Operating Margin at -1601.00%, Profit Margin at -288.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -21.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
WHWK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WHWK's Price-to-Sales ratio of 23.71x trades at a 24% premium to its historical average of 19.05x (43th percentile). The current valuation is 8% below its historical high of 25.76x set in Mar 2026, and 123% above its historical low of 10.65x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~11.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Whitehawk Therapeutics, Inc. (WHWK) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Whitehawk Therapeutics, Inc. is in a turnaround phase, with management focused on restoring profitability. Revenue reached 7M with 100% decline year-over-year. The company is currently unprofitable, posting a -288.3% profit margin.
Key Findings
Spending 266% of revenue (19M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -288.3% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Whitehawk Therapeutics, Inc..
Bottom Line
Whitehawk Therapeutics, Inc. is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:25:12 AM
About Whitehawk Therapeutics, Inc.(WHWK)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. The company is headquartered in Morristown, New Jersey.